Literature DB >> 30292166

Proton therapy for low-grade gliomas in adults: A systematic review.

Erik Thurin1, Petra W Nyström2, Anja Smits3, Katja Werlenius4, Anna Bäck5, Ann Liljegren6, Eva-Lotte Daxberg6, Asgeir Store Jakola7.   

Abstract

For adult patients with diffuse low-grade glioma (LGG) proton therapy is an emerging radiotherapy modality. The number of proton facilities is rapidly increasing. However, there is a shortage of published data concerning the clinical effectiveness compared to photon radiotherapy and potential proton-specific toxicity. This study aimed to systematically review and summarize the relevant literature on proton therapy for adult LGG patients, including dosimetric comparisons, the type and frequency of acute and long-term toxicity and the clinical effectiveness. A systematic search was performed in several medical databases and 601 articles were screened for relevance. Nine articles were deemed eligible for in-depth analysis using a standardized data collection form by two independent researchers. Proton treatment plans compared favorably to photon-plans regarding dose to uninvolved neural tissue. Fatigue (27-100%), alopecia (37-85%), local erythema (78-85%) and headache (27-75%) were among the most common acute toxicities. One study reported no significant long-term cognitive impairments. Limited data was available on long-term survival. One study reported a 5-year overall survival of 84% and 5-year progression-free survival of 40%. We conclude that published data from clinical studies using proton therapy for adults with LGG are scarce. As the technique becomes more available, controlled clinical studies are urgently warranted to determine if the potential benefits based on comparative treatment planning translate into clinical benefits.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Low grade glioma; Proton therapy; Radiation; Systematic review

Mesh:

Year:  2018        PMID: 30292166     DOI: 10.1016/j.clineuro.2018.08.003

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Managing an altered social context-Patients experiences of staying away from home while undergoing proton beam therapy.

Authors:  Marie-Louise Möllerberg; Ulrica Langegård; Emma Ohlsson-Nevo; Per Fransson; Birgitta Johansson; Karin Ahlberg; Katarina Sjövall
Journal:  Nurs Open       Date:  2020-04-14

2.  Spatial distribution of malignant transformation in patients with low-grade glioma.

Authors:  Asgeir S Jakola; David Bouget; Ingerid Reinertsen; Anne J Skjulsvik; Lisa Millgård Sagberg; Hans Kristian Bø; Sasha Gulati; Kristin Sjåvik; Ole Solheim
Journal:  J Neurooncol       Date:  2020-01-09       Impact factor: 4.130

3.  Establishment and Preliminary Characterization of Three Astrocytic Cells Lines Obtained from Primary Rat Astrocytes by Sub-Cloning.

Authors:  Fabio Caradonna; Gabriella Schiera; Carlo Maria Di Liegro; Vincenzo Vitale; Ilenia Cruciata; Tiziana Ferrara; Pietro D'Oca; Riccardo Mormino; Simona Maria Angela Rizzo; Italia Di Liegro
Journal:  Genes (Basel)       Date:  2020-12-13       Impact factor: 4.096

4.  Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy.

Authors:  Ulrica Langegård; Per Fransson; Thomas Bjork-Eriksson; Birgitta Johansson; Emma Ohlsson-Nevo; Katarina Sjövall; Karin Ahlberg
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-02-12

5.  Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas.

Authors:  Camilla S Byskov; Christian R Hansen; Rikke H Dahlrot; Lene Haldbo-Classen; Charlotte A Haslund; Flemming Kjær-Kristoffersen; Thomas O Kristensen; Yasmin Lassen-Ramshad; Slávka Lukacova; Aida Muhic; Petra W Nyström; Britta Weber; Jesper F Kallehauge
Journal:  Phys Imaging Radiat Oncol       Date:  2021-11-28

6.  Defining Clinical Indications of Proton Beam Therapy at National Level in the Kingdom of Saudi Arabia.

Authors:  Hussain AlHussain; Ali Balbaid; Robert Malyapa; Majid AlOthman; Yasser A Bahadur; Mutahir A Tunio; Mushabbab Al Asiri
Journal:  Saudi Med J       Date:  2019-09       Impact factor: 1.484

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.